Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBITDA Margin (2019 - 2025)

Avidity Biosciences (RNA) has disclosed EBITDA Margin for 7 consecutive years, with 7085.67% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 350487.0% year-over-year to 7085.67%, compared with a TTM value of 3226.43% through Dec 2025, down 29420.0%, and an annual FY2025 reading of 3652.2%, down 71998.0% over the prior year.
  • EBITDA Margin was 7085.67% for Q4 2025 at Avidity Biosciences, down from 1398.41% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 881.73% in Q1 2021 and bottomed at 7368.66% in Q1 2025.
  • Average EBITDA Margin over 5 years is 2700.79%, with a median of 2085.23% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 171982bps in 2025, while the deepest fall reached -540862bps in 2025.
  • Year by year, EBITDA Margin stood at 2090.93% in 2021, then rose by 14bps to 1795.09% in 2022, then tumbled by -48bps to 2664.84% in 2023, then crashed by -34bps to 3580.79% in 2024, then plummeted by -98bps to 7085.67% in 2025.
  • Business Quant data shows EBITDA Margin for RNA at 7085.67% in Q4 2025, 1398.41% in Q3 2025, and 4114.97% in Q2 2025.